ClinicalTrials.gg
Active, not recruitingNCT07305974Updated Oct 13, 2026

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

A Phase 2 interventional study of RG002C0106 and placebo subcutaneous administration in IgA Nephropathy (IgAN), sponsored by Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 13, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Planned enrollment
80th of 109
30 · median 84
Started
2025
with 19 others
Phase 2
27 of 127
14 open now
Primary completion
2029-03
later than 63 of 72 live
Registered
98th of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 80th largest by planned enrollment of the 109 interventional ones that give a count, is one of 20 that started in 2025, is one of 27 in phase 2, reaches primary completion later than 63 of the 72 other live ones, and was the 98th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

This study looks at how well and safely RG002C0106 works for patients with certain kidney disease: primary IgA nephropathy. It's a phase IIa trial done at several locations where both patients and doctors unknow what treatment is being given.

Read the detailed description

This is a Phase IIa, multicenter, double-blind clinical trial designed to evaluate the efficacy and safety of RG002C0106 in patients with primary IgA nephropathy. The primary objective is to assess the efficacy of RG002C0106 in reducing urinary protein excretion and preserving renal function in these patients. Secondary objectives include characterization of the safety profile, pharmacokinetics, and pharmacodynamics of the treatment

03

Conditions studied

  • IgA Nephropathy (IgAN)

Keywords

  • IgAN
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in the clinical trial and sign the form (ICF);
  2. Male or female participants aged 18 to 65 years (inclusive) at the time of signing the ICF;
  3. Body weight ≥ 40 kg;
  4. Negative blood pregnancy test result at screening for female participants of ;
  5. Renal pathology results within 10 years prior to screening confirming a diagnosis of primary IgA nephropathy;
  6. 24-hour urinary protein ≥ 0.75 g/24 h during the screening period;
  7. Estimated (eGFR) (calculated using the creatinine-based CKD-EPI formula) ≥ 30 mL/min/1.73 m² during the screening period;
  8. Must have received vaccination against Neisseria meningitidis (serogroups A, C, W, Y) and Streptococcus pneumoniae infections at least 2 weeks prior to the first dose of the product and provide proof of such vaccination;
  9. Participants must agree and require their partners to use adequate from the time of signing the ICF, throughout the study, and for at least 3 months after the study ends . Male participants must not donate sperm for at least 6 months after the last dose of the investigational product.

Exclusion criteria

Exclusion Criteria:

  1. Patients with secondary IgA nephropathy ;
  2. Renal pathology shows renal tubular atrophy or interstitial fibrosis ≥ 50%; or crescent formation in ≥ 50% of glomeruli ;
  3. Acute kidney injury or rapidly progressive glomerulonephritis within 4 weeks prior to screening ;
  4. Patients with nephrotic syndrome, defined as: 24-hour urinary protein (24h-UP) >3.5 g with hypoalbuminemia (serum albumin \<3.0 g/dL), hypercholesterolemia (total cholesterol >350 mg/dL), and edema;
  5. Any of the following abnormal laboratory results at screening:

    • (ALT) > 2 × (ULN);
    • Total (TB) > 1.5 × ULN. However, for patients with a confirmed diagnosis of Gilbert's syndrome, if TB > 1.5 × ULN but conjugated bilirubin \< ULN, they may be enrolled;
  6. Positive test results at screening for , Ab,-IgG, or TP-Ab;
  7. Poorly controlled type 1 or type 2 diabetes during the screening period ;
  8. Persistent elevated blood pressure during the screening period ;
  9. Patients with immunodeficiency diseases;
  10. Patients with splenic insufficiency (e.g., asplenia or history of splenectomy);
  11. History of kidney transplantation or organ transplantation (including bone marrow transplantation, stem cell transplantation, etc.);
  12. Suspected or confirmed history of hereditary complement deficiency;
  13. History of any tumor within 5 years before screening, except for the following: basal cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, and squamous cell carcinoma of the skin that have been completely cured after treatment;
  14. History of meningococcal infection within 12 months before screening;
  15. Active or suspected viral, bacterial, fungal, or parasitic infection within 14 days prior to product administration;
  16. History of allergic reactions to oligonucleotides or N-acetylgalactosamine (GalNAc);
  17. History of intolerance to subcutaneous injections or significant abdominal scarring that may impede administration or local tolerance assessment of the investigational product;
  18. Treatment with small-molecule complement inhibitors (e.g., iptacopan) within 3 months prior to investigational product administration, or previous treatment failure or intolerance;
  19. History of clinically significant severe infection within 3 months prior to screening, as determined by the investigator;
  20. Major surgery or severe trauma within 3 months prior to investigational product administration, incomplete recovery, or planned surgery during the study;
  21. Participation in any investigational drug or medical device clinical trial within 1 month prior to investigational product administration (excluding screen failures);
  22. Any other condition considered by the investigator to make the participant unsuitable for inclusion.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental: RG002C0106

    Randomly enrolled subjects receiving the investigational drug will receive subcutaneous injection for administration

    Drug: RG002C0106

  • Placebo comparator
    Placebo Comparator: placebo

    Randomly enrolled subjects receiving placebo will receive subcutaneous injection for administration

    Drug: placebo subcutaneous administration

Interventions

  • DrugRG002C0106

    RG002C0106 for subcutaneous (SC) injection

  • Drugplacebo subcutaneous administration

    The placebo is made of normal saline.

06

What researchers measure

Primary outcomes

  1. The percentage change from baseline in the mean 24hUPCR)at Week 24 after the first subcutaneous admini;

    Time frame: up to 169 days

  2. Incidence of adverse events (AEs) and serious adverse events (SAEs) related to the investigational drug.

    Time frame: up to 169 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Mar 2029, 42 months after the start.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2025
First posted
Dec 26, 2025
StartActual
Sep 8, 2025
Primary completionEst.
Mar 31, 2029
CompletionEst.
Mar 31, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07305974
Lead sponsor
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
Responsible party
Sponsor
First posted
Dec 26, 2025
Start date
Sep 8, 2025
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion